anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a preventing and treating agent for virus infection, especially rhinovirus infection by including ICAM-1 fragment or a fragment of its functional derivative. CONSTITUTION: This preventing and treating agent includes a fragment of ICAM-1 (intercellular adhesive molecule), e.g. domains 1, 2, 3, 4 and 5 of the ICAM-1, especially domain 1 of the ICAM-1, or a fragment of a functional derivative of the ICAM-1, e.g. the one having a prescribed amino acid at a directed position by replacement of amino acid (e.g. A3GL or L27 at Q1T, R13, D26QP), and administered to a patient required of treatment to treat a disease infected by a main serum type Rhinovirus in genus picornavirus, A-type Coxackie virus and Mengo virus. The presence of a virus infection is diagnosed by incubating a functional derivative of the ICAM-1 labeled so as to be detected with a biological sample.
Pelvic organ prolapse (POP), a downward descent of the vagina and/or uterus through the vaginal canal, is a prevalent condition affecting up to 40% of women. Several risk factors of POP have been identified, including childbirth, connective tissue defects, and chronic intra-abdominal pressure; however, the underlying etiologies of POP development are not fully understood, leading to a high burden on patients and the healthcare systems. The uterosacral ligaments are key support structures of the uterus and upper vagina. Our previous work describes observed histopathological changes in uterosacral ligament (USL) tissue and demonstrates the presence of neutrophils in a subgroup of POP individuals. This presence of neutrophils prompted an examination for the presence of a broader spectrum of inflammatory cell types in the USL. Immunohistochemical staining was performed to identify neutrophils, lymphocytes, macrophages, and mast cells outside of the vasculature. All 4 inflammatory cell types were increased in the POP-HQ system-defined POP-Inflammatory (POP-I) phenotype USL tissue relative to the USL tissues of control or other POP-HQ phenotypes. Focal T-lymphocyte and macrophage co-accumulations were observed in the arterial walls from some patients of the POP-vascular (POP-V) phenotype suggesting previous arterial injury. In addition, 1 control and 2 POP-V subjects' USLs contained arterial wall foamy macrophages, evidence of atherosclerosis. These findings further support a complex etiology for POP and indicate that personalized approaches to preventing and treating the condition may be warranted.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, include those of SOGROYA or other growth hormone analogs.

No anti-somapacitan-beco antibodies were detected in the clinical trials in adult patients with GHD.

Anti-somapacitan-beco binding antibodies were evaluated in samples collected at baseline, week 13, and week 52 of treatment in the 52-week main period of the phase 3 trial in pediatric patients with GHD receiving somapacitan-beco. Of the 132 subjects exposed to somapacitan-beco, 16 (12.1%) showed detectable binding antibodies to somapacitan-beco at any time during the main period of the trial following exposure to SOGROYA. 14 out of 16 subjects showed detectable binding antibodies to somapacitan-beco only at one timepoint. Of the 68 patients exposed to daily somatropin, detectable binding antibodies were detected in 7 (10.3%) children. Of these, 6 children had positive antibody samples only at one timepoint. There was no identified clinically significant effect of anti-drug antibodies on pharmacokinetics, pharmacodynamics, safety, or effectiveness of SOGROYA over the treatment duration. No neutralizing antibodies to somapacitan-beco were detected.
A standard cold pack chilled to -4°C will be applied to the arterial puncture site for 2 minutes. Following antiseptic cleaning and the physician will immediately perform the arterial blood sampling procedure with heparinized 3mL arterial blood gas syringe with a 22G x 1" needle.
554,014. Vitamins; fatty oils ; antioxidants. NATIONAL OIL PRODUCTS CO. Dec. 9, 1941, No. 15851. Convention date, Dec. 11, 1940. [Class 2 (iii)] Fatty oils are distilled under high vacuum after being subjected to an extraction treatment comprising extracting the oil at an elevated temperature with an aliphatic or alicyclic solvent miscible with the oil at temperatures above mean atmospheric temperature but partly immiscible at temperatures below mean room temperature, cooling the mixture and removing the solvent layers (c.f. Specifications 547,486 and 549,447). This extraction removes the free fatty acids, highly unsaturated glycerides, nitrogenous compounds, the odiferous and bad tasting ingredients, sterols, anti-oxidants and fat soluble vitamins present in the alcoholic form. Any fatty oil may be treated, namely those containing fat 'soluble vitamins A, D, E and K such as the fish liver oils, palm oil, wheat germ oil, rice germ oil, alfalfa seed oil and tomato seed oil and also fatty oils such as soyabean oil, wheat bran oil, corn oil, olive oil, sesame oil, cotton seed oil, coconut oil, rice oil, linseed oil, oiticia oil, teaseed oil, perilla oil, ground nut oil, poppy seed oil, egg oil, peanut oil and whale oil. By distilling at 140-250‹C. at a pressure below 0.1 mm. the residue obtained by extracting, as above described, an oil containing vitamins A and/or D, a fraction is obtained having most of the vitamin esters. When the oil contains only a small quantity of glycerides having the same boiling points as the vitamin esters, it is desirable to add some of the former to facilitate recovery of the vitamin esters. Separation of the vitamin A and D esters may be effected by collecting two separate fractions. Antioxidants, such as those prepared according to the process of Specification 550,983, and indicators may be added to the fatty residues before distillation. Anti-oxidants and sterols may be recovered from the fractions of the oils extracted.
Patients in this arm will receive intravenous chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
The study will enroll patients with type 1 diabetes who are already receiving twice-monthly non-face-to-face management by a dedicated education nurse through the Type 1 Diabetes Home Care Project and Educational Consultation program. The control group will continue their current treatment and non-face-to-face diabetes management.
Participants will receive a single 300 mg dose of STI-1558 or placebo. Cohort 1 will dose 6 subjects to STI-1558 and 2 subjects to placebo.
Background: Despite availability of evidence-based programs for diabetes prevention, few strategies exist to promote patients' interest in them. Strategies should be developed for racial/ethnic minority women with a history of gestational diabetes (GDM), who face exceptionally high risk for chronic diabetes. We previously found that a theory-based outreach message containing a streamlined values affirmation-two sentences prompting individuals to reflect on core personal values-increased women's likelihood of demonstrating interest in a preventive program. Extending this work, this pilot trial tests whether the values affirmation outreach message is as acceptable as (non-inferior to) a standard outreach message among African-American and Latina women.

Methods: Two-arm, parallel-group, randomized trial among English- and Spanish-speaking minority women with prior GDM and overweight/obesity in a healthcare system. Within an online survey, participants are randomized to read an outreach message promoting an existing preventive program. The message contains either a values affirmation (intervention condition) or no affirmation (control condition).
PROBLEM TO BE SOLVED: To obtain an antiseptic microbicide which can exclude or reduce the doses of conventional antiseptic microbicides, e.g. paraben, benzoic acid and the like, and possesses excellent antimicrobial potency by including a 1,2- alkanediol with a specific carbon number. SOLUTION: This antiseptic microbicide contains a 1,2-alkanediol (e.g. 1,2- pentanediol of formula II, 1,2-hexanediol of formula III or 1,2-octanediol of formula IV) of formula I [(n) is 1-7]. The compound of formula I can be blended with a composition for applying to the human body in a proportion of 0.05-20 wt.%. When 1,2-pentanediol is particularly used, it is favorable to be blended in a proportion of 1-10 wt.%. In addition, a combination of photosensitizer 201 of formula V, benzoic acid or its salt, phenoxyethanol and 4-isopropyl-3- methylphenol can be blended with the compound of formula I.
This research will eventually lead to the identification of inherited genetic changes that cause Barrett's esophagus and esophageal cancer. It will help the investigators develop better methods for preventing or identifying esophageal cancer at an early curable stage.

The capsule can be swallowed with a few sips water. Once the capsule is advanced to 45-50 cm from the incisors and reaches the stomach the balloon is inflated to a size of 16 mm with 5.5 cc air. It is withdrawn until a tug is felt to locate the gastroesophageal junction (GEJ). The inflated balloon is then pulled back 3 to 5 cm to sample the distal esophagus, then completely deflated to cause inversion of the biospecimen into its protective capsule, and then withdrawn. The balloon is re-inflated outside the patient and the obtained sample is clipped with scissors into a vial and frozen. The collected biospecimen will be stored frozen for later DNA extraction and assay. The vials will be labeled with a coded sample number. In a pilot study of 120 subjects this capsule esophageal sampling was performed with no adverse events reported. Similar esophageal sampling devices have been reported on over 1600 patients with no adverse events.

All patients will also undergo standard EGD. Patients with BE or EAC will have standard of care surveillance and diagnostic biopsies. All cases and controls will have research esophageal brushings from the BE/EAC and distal esophagus/gastric cardia, respectively. Cases and controls will also obtain research brushings from the proximal normal squamous esophagus. Research mucosal biopsies will also be obtained from the BE and EAC epithelium as well as normal stomach and duodenum in cases and from the gastric cardia and the distal squamous esophagus as well as normal stomach and duodenum in controls. Biopsies from BE and EAC will be directed by using high definition narrow band imaging. Biospecimens, brushings and biopsies, will be snap frozen at bedside and stored for future research assays. Although we do not anticipate any problems with our non-endoscopic balloon screening, these archived pathology samples and snap frozen samples will be available for assay in case we fail to detect our markers in patients with BE diagnosed at EGD or experience a high false positive rate. Subjects who undergo non-endoscopic sampling of the distal esophagus will be asked questions that rate their discomfort on a Likert scale and also asked questions comparing the non-endoscopic sampling study with an EGD.
The invention belongs to the technical field of biomedical antibacterial materials, and discloses a cationic cholic acid polyester antibacterial peptide, and a preparation method and application thereof. The cationic cholic acid polyester antibacterial peptide is more than one of formula I or formula II, wherein m is an integer greater than 0, and n is an integer greater than 0. The invention also discloses a preparation method of the cationic cholic acid polyester antibacterial peptide. The cholic acid polyester antibacterial peptide has higher surface positive charge, has obvious antibacterial capability on staphylococcus aureus, escherichia coli and pseudomonas aeruginosa, and has good blood compatibility. Meanwhile, the cholic acid polyester antibacterial peptide has an obvious bacteriostatic action on staphylococcus aureus as an antibacterial coating. The cationic cholic acid polyester antibacterial peptide is used in the field of biomedical materials.
Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse. Each subject will receive a handout and a sleep hygiene log.Subjects will be told to record their daily compliance with sleep hygiene instructions using yes/no questions in the sleep hygiene log.
A system for providing automated case management and reporting via artificial intelligence is provided. The system interacts with a user to obtain information from the user, which is then provided to an artificial intelligence engine to determine a medical complaint of the user. The artificial intelligence engine proceeds to automatically generate a digital record for the user that includes a predicted assessment and plan for treating the medical complaint. If standing order protocols exist, the digital records may be finalized and provided to the user, to a medical billing system, and to third parties for review and processing. Otherwise, the system may provide the digital record to a physician for further review to confirm the predictions and information associated with the digital record or to update the digital record. The digital record is then finalized and reported to the user, the medical billing system, and other third parties.
Complications from RBS are defined as those requiring re-operation or surgical interventions to evacuate blood, blood clot, bloody fluid, and air accumulation within the operative site after closure of the surgical wound. This is a prospective multicenter observational post-market study with a retrospective component. The study is open to up to five (5) German sites enrolling a consecutive cohort of cardiac surgery patients.

There are two conditions for participation in this registry. First, sites are required to enter into the study database anonymized matched historical data elements from a cohort of cardiac surgery patients done over the preceding 12 to 24-month period (Phase 0). These retrospective data elements will be used as baseline information for the purpose of comparative analyses with the prospective data sets. Second, sites that have not been using the PleuraFlow System before enrolling patients to this study are required to participate in a roll-in phase (Phase 1). The purposes of the roll-in phase are to allow the users at participating sites to familiarize themselves with the product use and with ACT, to implement Clinical Use Protocols provided by ClearFlow, Inc. to all commercial users as part of product training, and to demonstrate consistency and compliance with the clinical use protocols.
<P>PROBLEM TO BE SOLVED: To provide a crude drug-containing composition which can daily, easily and safely be ingested and by which amelioration of metabolic syndrome, inhibition of obesity, etc. can be expected; and to provide a metabolic syndrome-ameliorating composition, obesity-inhibiting composition, composition to inhibit increase of body fat, composition to inhibit increase of neutral fat in blood and liver function-ameliorating composition, which are high in safety and excel in ameliorative effects.  <P>SOLUTION: The crude drug-containing composition includes crude drug components involving Garcinia, Terminalia beleria, Commiphora mukul, Gymnema sylvestre, Boswellia serrata and Salacia reticulata. The crude drug-containing composition is applied to the metabolic syndrome-ameliorating composition, obesity-inhibiting composition, composition to inhibit increase of body fat, composition to inhibit increase of neutral fat in blood and liver function-ameliorating composition, as an active component. Where one or more crude drug components selected from the group consisting of Emblica officinalis, Azadirachta indica, Berberis aristata (Indian barberry), Andrographis paniculata, Momordica charantia, Tinospora crispa, Tinospora sinensis, Allium sativum, Curcuma longa, Coleus forskohlii, Piper longum, Zingiber officinale and Piper nigrum, are preferably added to the crude-containing composition.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Chronic cocaine abuse has been documented to produce cognitive impairments in various domains. The observed cognitive deficits in the substance abuse population include, but are not restricted to, attention, concentration, verbal and nonverbal memory, problem solving and abstract reasoning. Our recent studies (IRB Protocol # 3998) demonstrated that in cocaine dependent participants such cognitive deficits have been shown to: 1) negatively effect retention and 2) impede the ability of the drug abuser to benefit from cognitive behavioral therapy- relapse prevention (CBT-RP) that requires participant to attend to novel stimuli, integrate new information with existing stores, and translate information into behavior change (Aharonovich, Hasin \& Nunes, 2003; Aharonovich et al, in press). Furthermore, the toxic effects of cocaine together with withdrawal symptoms, such as fatigue and hypersomnia make it difficult to fully engage in any psychosocial intervention including CBT-RP.

Recent findings indicate that cocaine dysregulates reward-related glutamate pathways (Dackis \& O'Brien, 2003; Kalivas et al, 2003). Modafinil is a medication known to improve attention, increase wakefulness, energy, and alertness in part by increasing glutamate levels. In light of this work and the negative affect of cognitive impairments on treatment outcomes, testing cognitive enhancing medications that act on glutamate pathways is a novel promising strategy for improving treatment for cocaine dependence. Modafinil is approved for sleep disorders and is a relatively safe medication for cocaine-dependent participants as it has a low abuse potential and has shown promise in a double blind placebo controlled trial for cocaine dependence (Rush et al, 2002; Jasinski, 2000, Dackis et al, 2005). We therefore propose a double blind placebo controlled 12-week exploratory pilot study of modafinil, a "wakefulness agent," in conjunction with sessions of CBT-RP enhanced with motivational interviewing components.
FIELD: medicine. ^ SUBSTANCE: invention relates to cosmetic composition. Cosmetic composition, of anti-aging action, containing alcohol or water-alcohol extract from seeds of plants Aframomum angustifolium or Longoza in cosmetically acceptable filler. Application of extract from seeds of plants Aframomum angustifolium or Longoza as cosmetic agent for production of cosmetic composition. Method of cosmetic care including local application on the skin of individual, who needs it, of cosmetically efficient against aging amount of extract from seeds of plants Aframomum angustifolium or Longoza. ^ EFFECT: said cosmetic composition is efficient against aging. ^ 14 cl, 4 dwg, 7 ex
Laparoscopic repair: Pneumoperitoneum was performed to 12 mmHg. Herniary contents and sac are reduced releasing adhesions with diathermy or harmonic scalpel. Defects are repaired with a polytetrafluoroethylene (PTFE) patch (Dual Mesh; W.L Gore and Associates, FlagstaV, AZ USA) with double crown fixation as technique of Carbajo et al, ensuring exceed 3 cm edge of defect, using 5mm tackers (Protack, Autosuture; Tyco Healthcare, USA), reducing intrabdominal pressure to 8 mmHg. All operations were performed by experienced surgeons, over than 40 laparoscopic ventral hernia repairs.
In vitro maturation (IVM) is an assisted reproductive technology which consists in the retrieval of immature cumulus-oocyte complexes (COCs) from small antral follicles, followed by their in vitro maturation in specific culture conditions. Oocytes having reached metaphase II (MII) stage after 24 to 48 hours of IVM can then be fertilized. This procedure was first developed for patients presenting polycystic ovarian syndrome (PCOS), in order to avoid ovarian hyperstimulation syndrome (OHSS), an iatrogenic consequence of exogenous gonadotropins administration. However, the increasing use of GnRH antagonist protocols allowing ovulation trigger with GnRH agonist has dramatically reduced the indication of IVM in women at risk of OHSS. Yet, evidence indicate that IVM may be considered for patients presenting FSH resistance or contraindications to controlled ovarian stimulation. The recent development of female fertility preservation (FP) renewed interest to this technique. Indeed, it can be performed without any prior ovarian stimulation and whatever the phase of the menstrual cycle. Although it is still considered experimental, oocyte vitrification following IVM has been applied in different groups of patients, in particular those diagnosed with breast cancer, autoimmune or ovarian diseases. In physiologic conditions, final follicular maturation is induced by a double FSH and LH release which occurs when the dominant follicle reaches approximately 17 to 20 mm in diameter. This gonadotropin surge usually precedes the follicular rupture and mature oocyte release from 36 to 40 hours. In case of an assisted reproductive treatment, two strategies can be used to reproduce this hormonal signal: (i) either an injection of hCG, which binds to the LH receptor on granulosa cells, (ii) or a GnRH agonist (GnRHa) administration which induces an endogenous double peak of LH and FSH through a "flare up effect". Miming common practice for in vitro fertilization, priming with hCG or GnRHa injection 36 hours before the COCs retrieval has been suggested for patients undergoing IVM procedure in order to improve oocyte maturation rates and further IVM outcomes. Indeed, it is hypothesized that these iatrogenic hormonal activities might enhance the final oocyte maturation in vivo, therefore shortening the duration of the overall IVM process. Actually, in PCOS patients, several line of evidence indicate that IVM outcomes are improved after hCG priming. This positive effect might be explained by a premature expression of LH receptors on granulosa cells of small antral follicles \<10 mm in diameter. Nevertheless, in normo-ovulatory non PCOS patients, LH receptor expression in these follicles remains very low, questioning the relevance of providing LH activity to improve oocyte maturation during IVM cycles performed for FP. The present investigation aimed to test whether the absence of therapeutic intervention prior to oocyte retrieval modifies IVM outcomes when compared with cycles primed either with recombinant hCG or GnRH agonist in breast cancer patients.
When the epidural needle is inserted initially, it is typically connected to a syringe filled with 2-3 ml or air or saline. This is used to help identify the placement of the epidural needle. Both air and saline are commonly used and it is not clear and debatable which is a better method to identify the correct placement of the needle. Some doctors like using air in the syringe because when a drop of clear fluid returned from the smaller spinal needle, it would be clear to indicate the correct space for first dose of medicine since no pre-existing fluid was used. In group Saline, 3 mL of saline will be used. In group Air, 3 mL of air will be used in the syringe during the procedure.

The medicine will be administered in the usual manner the doctor has identified the correct location for administration. The amount of pain during labor will be assessed the patient giving a number from 0 to 10 with 0 being no pain and 10 being the worst pain.